Poolbeg Pharma (LON:POLB) Stock Price Up 0.6% – Still a Buy?

Shares of Poolbeg Pharma PLC (LON:POLB) rose 0.6% on Thursday . The company traded as high as GBX 8.50 and last traded at GBX 8.40. Approximately 1,320,721 shares changed hands during mid-day trading, a decline of 34% from the average session volume of 2,001,177 shares. The stock had previously closed at GBX 8.35.

Wall Street Analysts Forecast Growth

Separately, Shore Capital Group reissued a “house stock” rating on shares of Poolbeg Pharma in a research report on Monday, July 13th.

Poolbeg Pharma Trading Down 0.0%

The company’s 50 day moving average price is GBX 7.60 and its two-hundred day moving average price is GBX 6.09. The firm has a market cap of £64.11 million, a PE ratio of -8.93 and a beta of 1.83.

Poolbeg Pharma Company Profile

Poolbeg Pharma plc (AIM: POLB) is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company’s lead asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). As such, POLB 001 could increase the number of patients that can receive these life-saving treatments, thereby increasing the market opportunity.